Corvus Pharmaceuticals, Inc. (CRVS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth Lose.
22/55
2.0 / 5 stars
All 55 Win/Lose results and 65 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 5 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseCRVS / S&P 2.12% / 15.20% |
No dataCRVS / S&P / 15.00% |
LoseCRVS / S&P -38.38% / 50.40% |
| 2026-Q11/2 |
WinCRVS / S&P 90.00% / -4.33% |
No dataCRVS / S&P / 11.30% |
LoseCRVS / S&P -45.83% / 27.70% |
| 2025-Q41/2 |
WinCRVS / S&P 4.48% / 2.65% |
No dataCRVS / S&P / 9.00% |
LoseCRVS / S&P -47.37% / 13.40% |
| 2025-Q31/2 |
WinCRVS / S&P 84.25% / 8.12% |
No dataCRVS / S&P / 4.61% |
LoseCRVS / S&P -44.57% / 13.45% |
| 2025-Q22/2 |
WinCRVS / S&P 25.79% / 10.94% |
No dataCRVS / S&P / 4.83% |
WinCRVS / S&P 125.00% / 10.63% |
| 2025-Q11/2 |
LoseCRVS / S&P -40.56% / -4.27% |
No dataCRVS / S&P / 4.98% |
WinCRVS / S&P 88.24% / 10.57% |
| 2024-Q41/2 |
LoseCRVS / S&P 1.33% / 2.41% |
No dataCRVS / S&P / 5.25% |
WinCRVS / S&P 69.64% / 6.15% |
| 2024-Q32/2 |
WinCRVS / S&P 190.11% / 5.89% |
No dataCRVS / S&P / 5.89% |
WinCRVS / S&P 43.75% / 6.11% |
| 2024-Q20/2 |
LoseCRVS / S&P 2.25% / 4.28% |
No dataCRVS / S&P / 5.38% |
LoseCRVS / S&P -47.62% / 5.12% |
| 2024-Q10/2 |
LoseCRVS / S&P 1.14% / 10.56% |
No dataCRVS / S&P / 5.71% |
LoseCRVS / S&P -42.05% / 5.59% |
| 2023-Q41/2 |
WinCRVS / S&P 20.55% / 11.69% |
No dataCRVS / S&P / 6.81% |
LoseCRVS / S&P -37.08% / 7.78% |
| 2023-Q30/2 |
LoseCRVS / S&P -36.24% / -3.27% |
No dataCRVS / S&P / 7.52% |
LoseCRVS / S&P -26.44% / -5.03% |
| 2023-Q22/2 |
WinCRVS / S&P 151.65% / 8.74% |
No dataCRVS / S&P / 9.50% |
WinCRVS / S&P 6.33% / -8.57% |
| 2023-Q11/2 |
LoseCRVS / S&P 7.06% / 7.50% |
No dataCRVS / S&P / 10.77% |
WinCRVS / S&P -1.12% / -15.69% |
| 2022-Q41/2 |
LoseCRVS / S&P 3.79% / 7.56% |
No dataCRVS / S&P / 11.88% |
WinCRVS / S&P -15.24% / -17.99% |
| 2022-Q30/1 |
LoseCRVS / S&P -17.27% / -4.88% |
No dataCRVS / S&P / 13.47% |
No dataCRVS / S&P / -1.41% |
| 2022-Q20/1 |
LoseCRVS / S&P -39.63% / -16.10% |
No dataCRVS / S&P / 13.71% |
No dataCRVS / S&P / 11.04% |
| 2022-Q10/1 |
LoseCRVS / S&P -31.95% / -4.60% |
No dataCRVS / S&P / 15.97% |
No dataCRVS / S&P / 42.23% |
| 2021-Q40/1 |
LoseCRVS / S&P -50.21% / 11.03% |
No dataCRVS / S&P / 15.00% |
No dataCRVS / S&P / 96.40% |
| 2021-Q31/1 |
WinCRVS / S&P 81.27% / 0.58% |
No dataCRVS / S&P / 10.77% |
No dataCRVS / S&P / 69.42% |
| 2021-Q20/1 |
LoseCRVS / S&P -13.31% / 8.55% |
No dataCRVS / S&P / 6.58% |
No dataCRVS / S&P / 51.81% |
| 2021-Q10/1 |
LoseCRVS / S&P -13.48% / 6.17% |
No dataCRVS / S&P / -1.06% |
No dataCRVS / S&P / 7.39% |
| 2020-Q40/1 |
LoseCRVS / S&P -11.22% / 12.15% |
No dataCRVS / S&P / -3.72% |
No dataCRVS / S&P / -33.42% |
| 2020-Q31/1 |
WinCRVS / S&P 47.43% / 8.93% |
No dataCRVS / S&P / -2.04% |
No dataCRVS / S&P / -27.10% |
| 2020-Q21/1 |
WinCRVS / S&P 28.91% / 20.54% |
No dataCRVS / S&P / -0.46% |
No dataCRVS / S&P / -27.11% |
| 2020-Q10/1 |
LoseCRVS / S&P -61.21% / -19.60% |
No dataCRVS / S&P / 3.47% |
No dataCRVS / S&P / -14.75% |
| 2019-Q41/1 |
WinCRVS / S&P 80.73% / 9.07% |
No dataCRVS / S&P / 5.36% |
No dataCRVS / S&P / 2.99% |
| 2019-Q30/1 |
LoseCRVS / S&P -19.52% / 1.70% |
No dataCRVS / S&P / 5.02% |
No dataCRVS / S&P / 0.21% |
| 2019-Q20/1 |
LoseCRVS / S&P -6.97% / 4.30% |
No dataCRVS / S&P / 6.64% |
No dataCRVS / S&P / 8.65% |
| 2019-Q10/1 |
LoseCRVS / S&P 9.54% / 13.65% |
No dataCRVS / S&P / 8.12% |
No dataCRVS / S&P / 14.29% |
| 2018-Q40/1 |
LoseCRVS / S&P -57.23% / -13.52% |
No dataCRVS / S&P / 9.05% |
No dataCRVS / S&P / 18.23% |
| 2018-Q30/1 |
LoseCRVS / S&P -21.86% / 7.71% |
No dataCRVS / S&P / 10.21% |
No dataCRVS / S&P / 19.06% |
| 2018-Q20/1 |
LoseCRVS / S&P -4.77% / 3.43% |
No dataCRVS / S&P / 9.03% |
No dataCRVS / S&P / 14.46% |
| 2018-Q11/1 |
WinCRVS / S&P 11.29% / -0.76% |
No dataCRVS / S&P / 7.68% |
No dataCRVS / S&P / 12.46% |
| 2017-Q40/1 |
LoseCRVS / S&P -35.01% / 6.64% |
No dataCRVS / S&P / 7.03% |
No dataCRVS / S&P / 13.82% |
| 2017-Q31/1 |
WinCRVS / S&P 31.74% / 4.48% |
No dataCRVS / S&P / 5.68% |
No dataCRVS / S&P / 17.57% |
| 2017-Q20/1 |
LoseCRVS / S&P -41.74% / 3.09% |
No dataCRVS / S&P / 4.83% |
No dataCRVS / S&P / 17.74% |
| 2017-Q11/1 |
WinCRVS / S&P 45.24% / 6.07% |
No dataCRVS / S&P / 3.67% |
No dataCRVS / S&P / 13.32% |
| 2016-Q40/1 |
LoseCRVS / S&P -13.07% / 3.82% |
No dataCRVS / S&P / 2.09% |
No dataCRVS / S&P / 7.05% |
| 2016-Q31/1 |
WinCRVS / S&P 15.36% / 3.85% |
No dataCRVS / S&P / 0.20% |
No dataCRVS / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CRVS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 156.45% | 20.78% |
| Annualized return | 156.45% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CRVS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 531.76% | 83.14% |
| Annualized return | 44.58% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CRVS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 8.08% | 319.30% |
| Annualized return | 0.78% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |